Hints and tips:
Related Special Reports
...Soriot already earns more than bosses of larger European pharmaceutical companies....
...The defence of Soriot’s pay raises the prospect of a split among big shareholders as they vote on a new deal....
...AstraZeneca has a market capitalisation of £171bn....
...“You can assume that we look at everything or at least most of it,” he said....
...It is one of about 80,000 remaining cases relating to Zantac that have prompted a combined hit of tens of billions of dollars to the values of the companies involved, with the drug’s developer GSK the most...
...Its latest results show a 6 per cent fall in sales in the first quarter of 2024, which the company attributed to the strength of the Swiss franc and declining sales of its Covid-19 treatment Ronapreve....
...Moderna and CureVac have also issued legal proceedings against the US and German partners, with the aim of obtaining a share of Comirnaty profits but also asserting their intellectual property for future...
...There have been a series of recent developments in the treatment of liver disease, which is the third-largest cause of early death in the UK and other high-income countries....
...Some of these bacteria are listed among the most critical priority pathogens by the WHO. The MBL enzymes break the structure of many existing antibiotics, destroying their efficacy....
...The UK-based pharmaceutical group reported revenue of $12.7bn, well ahead of consensus estimates of $11.9bn....
...The UK-based pharmaceutical group reported revenue of $12.7bn for the first quarter of 2024, an increase of 19 per cent, well ahead of consensus estimates of $11.9bn....
...China is one of the world’s largest makers of active pharmaceutical ingredients and antibiotics and a major supplier of drugs to the EU and US....
...highest of any company....
...Roche sales fell by 6 per cent in the first quarter of 2024 due to the strong Swiss franc and falling sales of its Covid-19 treatment Ronapreve....
...An employee had rushed to destroy sheets of data ahead of the arrival of inspectors by throwing acid on torn pieces of paper. After the inspection, Intas suspended production to address shortcomings....
...The study of the prevalence of the synthetic drug, the first research of its kind, said UK labs had found xylazine in 16 people, 11 of whom had died....
...“We know many of the problems are global and relate to fragile chains of imports from Asia, squeezed by Covid-19 shutdowns, inflation and global instability,” said Mark Dayan, the Nuffield Trust’s Brexit...
...Soriot would also be in line for a bonus worth up to 300 per cent of his base salary, compared with the prior policy of 250 per cent....
...Soriot would also be in line for a bonus worth up to 300 per cent of his base salary, compared with the prior policy of 250 per cent. Read more here...
...AstraZeneca has reported successful trial results for one of its top cancer drugs, in a boost to the drugmaker’s ambitions for its medication to be a treatment option for more than half of lung cancer patients...
...Shareholders will vote later today on a plan to raise Soriot’s pay by £1.8mn to a maximum of £18.7mn in 2024....
...“More investment, better jobs in every corner of the country,” said Jeremy Hunt, announcing the investment....
...Sales of its diabetes and obesity drugs have sent Novo Nordisk’s market capitalisation soaring but the company has also set a goal of diversifying, including into the treatment of cardiovascular diseases...
...This will go to innovative companies, with the aim of unlocking more than £1bn of total private capital.Pensions provider Phoenix Group will match the £250mn investment....
...“If our pilot data are confirmed, it is going to dramatically change the quality of life of the patients,” said Rascol....
International Edition